RITUXAN + GCC IS THE 1ST AND ONLY INDUCTION AND FOLLOW‑UP TREATMENT FDA-APPROVED FOR GPA & MPA[13]*

  • Rituxan + GCC is the first and only FDA-approved induction therapy to achieve complete remission in GPA and MPA.[5]
    • Induction treatment: In the RAVE Trial, 64% of patients induced with Rituxan and GCC achieved complete remission (BVAS/GPA=0 and 0 mg prednisone) at 6 months compared with 53% of patients treated with CYC followed by AZA, thereby demonstrating non-inferiority. [11]
    • Follow-up treatment: In the MAINRITSAN study, 5% of patients treated with the rituximab regimen experienced a major relapse at 28 months vs 29% of patients treated with AZA + GCC[13]

Rituximab regimen=Roche-manufactured, European Union—approved rituximab + GCC.

The BOXED WARNINGS for Rituxan include: Infusion Reactions, Severe Mucocutaneous Reactions, Hepatitis B Virus (HBV) Reactivation, and Progressive Multifocal Leukoencephalopathy (PML).

*Follow-up treatment with Rituxan may be used in patients who have achieved disease control with Rituxan or with other immunosuppressants.

Rituxan: a legacy of experience

Rituxan milestones from 2002 to today

Efficacy and Safety data

Review efficacy and safety data from the induction and follow-up treatment trials

Patient access

Get information and resources for patient financial support and programs

AZA, azathioprine; CYC, cyclophosphamide; GCC, glucocorticoids; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis.
The Birmingham Vasculitis Activity Score for Granulomatosis with Polyangiitis (BVAS/GPA). For new or worse disease ranges from 0 to 68, with higher scores indicating more active disease. A BVAS/GPA of 0 indicates remission.
Major relapse was defined by the reappearance of clinical and/or laboratory signs of vasculitis activity (BVAS>0) that could lead to organ failure or damage, or could be life-threatening.